Nuveen LLC Makes New Investment in Adaptive Biotechnologies Corporation $ADPT

Nuveen LLC acquired a new position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,295,117 shares of the company’s stock, valued at approximately $9,623,000. Nuveen LLC owned about 0.85% of Adaptive Biotechnologies at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Bridgefront Capital LLC bought a new stake in Adaptive Biotechnologies in the 4th quarter worth approximately $80,000. Personal CFO Solutions LLC bought a new stake in Adaptive Biotechnologies in the 1st quarter worth approximately $84,000. Blair William & Co. IL bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at approximately $84,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at approximately $87,000. Finally, Walleye Capital LLC bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at approximately $94,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Up 2.9%

ADPT opened at $13.00 on Friday. The business has a fifty day moving average of $11.42 and a 200 day moving average of $9.43. Adaptive Biotechnologies Corporation has a 52-week low of $3.98 and a 52-week high of $13.40. The stock has a market cap of $1.98 billion, a P/E ratio of -15.85 and a beta of 1.92.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The company had revenue of $49.94 million during the quarter, compared to analysts’ expectations of $49.40 million. During the same quarter in the previous year, the business earned ($0.31) EPS. Adaptive Biotechnologies’s revenue was up 36.3% compared to the same quarter last year. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ADPT shares. Craig Hallum started coverage on Adaptive Biotechnologies in a research report on Wednesday, June 18th. They set a “buy” rating and a $15.00 target price on the stock. Piper Sandler boosted their target price on Adaptive Biotechnologies from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. boosted their target price on Adaptive Biotechnologies from $10.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their target price on Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group boosted their target price on Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.38.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.